ArticlePlanta2025
Transcriptomics and network pharmacology analysis reveal key genes in alkaloid biosynthesis in Zephyranthes candida and therapeutic targets for LIHC.
Article in Planta, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Pharmacological Potential of PeruvianPlants (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
MAIN
conclusionThis study identified key enzyme-encoding genes involved in the biosynthesis of lycorine and galanthamine in Zephyranthes candida, and predicted four critical therapeutic targets of lycorine for liver hepatocellular carcinoma (LIHC). Amaryllidaceae alkaloids (AAs) comprise a unique class of isoquinoline alkaloids mainly found in plants of the Amaryllidaceae family. Zephyranthes candida (Lindl.) Herb., a bulbous geophyte within this family, produces lycorine and galanthamine as its characteristic isoquinoline alkaloids. In this study, an in-depth analysis of the biosynthesis of these compounds in various tissues of the plant was conducted using transcriptomics and bioinformatics. Transcriptome databases were generated for roots, leaves, and bulbs of Z. candida. Key enzymes and differentially expressed genes (DEGs) associated with lycorine and galanthamine biosynthesis were screened, leading to the identification of two genes, ZcTYDC (DN4967_1) and ZcN4OMT (DN3779), based on correlation analysis. Subsequently, phylogenetic, structural modeling and molecular docking analyses of key enzymes were undertaken, followed by a detailed assessment of their characteristics and functions. A correlation was identified between the expression of genes encoding transcription factors (TFs) and major AAs biosynthetic enzymes in Z. candida. The expression levels of selected genes were determined by quantitative real-time polymerase chain reaction (qPCR), while the contents of lycorine and galanthamine in each tissue were detected by high-performance liquid chromatography (HPLC). Critical targets of lycorine in liver hepatocellular carcinoma (LIHC)-MMP9, IGF1, SRC, and CCNA2-were predicted using network pharmacology, gene expression profiling interactive analysis (GEPIA2), molecular docking, and visualization. This study provides a theoretical basis for further research on the biosynthesis of AAs, as well as support for the therapeutic application of lycorine in LIHC.
Indexed as
Identifiers
40640563What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.